ACTIVE STUDIES RECRUITING:

• W8M-MC-CWMM – Overweight and Obesity/With or without Type 2 Diabetes

A phase 2 Trial with the main purpose to investigate the effect of LY3305677 Compared with Placebo in Adult Participants with Obesity or Overweight with or without Diabetes. The study will last around 65 weeks.

Those meeting the eligibility criteria will receive trial-related procedures and the study medication without incurring any costs. Additionally, participants may be compensated for their time and travel. If deemed eligible, attendance of routine visits based on a specific schedule will be required.

• J4Z-MC-GIDI – Obesity and Overweight/ Type 2 Diabetes

The main purpose of this study is to see how well and how safely bimagrumab, tirzepatide, and the combination, work in lowering body weight in participants with obesity or overweight and type 2 diabetes. Participation in the study will last about 13 months.

Those meeting the eligibility criteria will receive trial-related procedures and the study medication without incurring any costs. Additionally, participants may be compensated for their time and travel. If deemed eligible, attendance of routine visits based on a specific schedule will be required.

• D5989C00001 (THARROS) – COPD (Chronic Obstructive Pulmonary Disease)

A Randomized, Double-blind, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease.

Those meeting the eligibility criteria will receive trial-related procedures and the study medication without incurring any costs. Additionally, participants may be compensated for their time and travel. If deemed eligible, attendance of routine visits based on a specific schedule will be required.

ACTIVE STUDIES NON-RECRUITING:

• NN9388-4894 (REIMAGINE 4) –Overweight and Obesity/T2DM

This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight and their blood sugar. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. Duration of the Trial is around 1.5 years.

Those meeting the eligibility criteria will receive trial-related procedures and the study medication without incurring any costs. Additionally, participants may be compensated for their time and travel. If deemed eligible, attendance of routine visits based on a specific schedule will be required.

• NN9388-4896 ( REIMAGINE 2) – T2DM/Overweight And Obesity

The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. Duration of the Trial is around 1.5 years.

Those meeting the eligibility criteria will receive trial-related procedures and the study medication without incurring any costs. Additionally, participants may be compensated for their time and travel. If deemed eligible, attendance of routine visits based on a specific schedule will be required.

• J2A-MC- GZGS – T2DM/Overweight/Obesity

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits.

Those meeting the eligibility criteria will receive trial-related procedures and the study medication without incurring any costs. Additionally, participants may be compensated for their time and travel. If deemed eligible, attendance of routine visits based on a specific schedule will be required.

• J1I-MC-GZBU – T2DM/Kidney Disease/Overweight and Obesity

The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will lasts around 31 weeks.

Those meeting the eligibility criteria will receive trial-related procedures and the study medication without incurring any costs. Additionally, participants may be compensated for their time and travel. If deemed eligible, attendance of routine visits based on a specific schedule will be required.

COMPLETED STUDIES:

  • Acasti Pharma – ACA-CAP-002 (TRILOGY2) – Hypertriglyceridemia – 2020

  • Eli Lilly and Co. – J1I-MC-GZBF – OBESITY – 2022

  • Eli Lilly and Co. – I8F-MC-GPHL (SURMOUNT 2) – T2DM/ Overweight/Obesity – 2023

  • Novo Nordisk – NN9536-4374 (STEP 2) – Overweight/Obesity – 2020

  • Novo Nordisk – EX9536-4388 (select) – Overweight/Obesity – 2023

  • Pfizer – C1061011 – Non-alcoholic steatohepatitis – 2021

  • CR845-310301 – CKD/Pruritus
  • J2A-MC- GZGS – T2DM/Overweight/Obesity
  • 901-C-2102 (CYPRESS Trial) – Diabetic Neuropathy
  • I8F-MC-GPHJ – Overweight/Obesity
  • NN9536-7545 (STEP-UP)- T2DM/Overweight/Obesity
  • NN9838-4609 (REDEFINE 2) – T2DM/ Overweight/Obesity

info@PlanItResearch.com